Zai Lab Ltd ADR (ZLAB) Stock Price, Quote & News

Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for commu...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 21 6163 2588

Website: www.zailaboratory.com

Address:

Building B, 899 Halei Road, Pudong, China

Spartrap Dec. 24 at 5:16 PM

$ZLAB perfect bounce off the lows. Bonus points for the utter stupidity of the ADR crowd👌🏻🔥

0 · Reply

Akwaba76 Dec. 23 at 4:54 PM

$ZLAB 🔥 The market is short-term, science is long-term. COBENFY’s non-dopamine MOA is the biggest innovation in schizophrenia in decades. SP volatility is noise — this is a franchise drug

0 · Reply

Spartrap Dec. 23 at 4:14 PM

$ZLAB hey folks, any thoughts on the apparent deprioritization of adagrasib (Krazati)? There were big hopes at some point IIRC and BMS (having BO Mirati since) has touted P3 confirmatory trial success since then in NSCLC. Yet Zai Lab still has to file for NMPA application it seems, and it doesn't appear anymore in the slide deck. I wonder why?

1 · Reply

DonCorleone77 Dec. 23 at 2:16 PM

$NVO $HII $SOC $ZIM $ZLAB PRE-MARKET MOVERS: Currently Higher: - Sable Offshore (SOC) up 19.2% after the Pipeline Hazardous Materials Safety Administration granted approval of the Las Flores Pipeline restart - Novo Nordisk (NVO) up 9.3% after Reuters reported the company's newly approved version of Wegovy in pill form is planned to go straight to U.S. self-pay channels in early January - HII (HII) up 1.6% after The Wall Street Journal reported on President Trump announcing that the U.S. Navy intends to build a new "Trump-class" battleship as part of the "Golden Fleet" initiative - ZIM Integrated (ZIM) up 7.9% after update on strategic review process - Zai Lab (ZLAB) up 2.0% after announcing that China's National Medical Products Administration approved the new drug application for Cobenfy for the treatment of schizophrenia in adults Currently Lower: - Johnson & Johnson (JNJ) down 0.9% after Reuters reported a Baltimore jury has ordered the company and its subsidiaries to pay more than $1.5B to a woman who said exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma

0 · Reply

DonCorleone77 Dec. 23 at 2:13 PM

0 · Reply

Spartrap Dec. 23 at 2:09 PM

$ZLAB FYI $BMY spent $14B in 2024 to acquire Karuna therapeutics for Cobenfy (KarXT). Zai Lab was much smarter and acquired the rights for Asia in 2021 so they got an excellent deal, with royalties in the low teens and modest milestone payments. Future blockbuster and you can buy it here for pennies!

1 · Reply

Spartrap Dec. 23 at 2:04 PM

$ZLAB excellent. Just in time to deepen the reversal

0 · Reply

Akwaba76 Dec. 23 at 1:34 PM

$ZLAB Merry X-mas https://www.businesswire.com/news/home/20251223179134/en/Zai-Lab-Announces-Approval-of-COBENFY-xanomeline-and-trospium-chloride-in-China-a-First-in-Class-Therapy-for-Schizophrenia

0 · Reply

Daniels_ Dec. 20 at 4:20 PM

$ZLAB China biotech tracking local sentiment, you need cross border volume and a breakout through resistance before leaning long

0 · Reply

Spartrap Dec. 16 at 6:41 PM

$ZLAB watching this like a hawk. Terrible chart but it makes no sense. Just the Vyvgart licence is worth 10-15% of ARGX MC. Capitulation should be close

1 · Reply

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

Dec 8, 2025, 7:00 AM EST - 16 days ago

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

Dec 7, 2025, 12:11 AM EST - 18 days ago

Zai Lab Announces Updates to China's National Reimbursement Drug List

Nov 11, 2025, 12:00 PM EST - 6 weeks ago

Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy)

Nov 7, 2025, 8:16 AM EST - 6 weeks ago

Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 6 weeks ago

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

Oct 31, 2025, 7:30 AM EDT - 7 weeks ago

Zai Lab Announces Participation in Investor Conferences in November and December 2025

Oct 24, 2025, 2:37 PM EDT - 2 months ago

Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript

Oct 24, 2025, 9:00 AM EDT - 2 months ago

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

Oct 15, 2025, 7:30 AM EDT - 2 months ago

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

Oct 13, 2025, 12:02 PM EDT - 2 months ago

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Sep 11, 2025, 8:02 AM EDT - 3 months ago

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Sep 9, 2025, 6:47 PM EDT - 3 months ago

Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 1, 2025, 8:00 PM EDT - 4 months ago

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

Aug 28, 2025, 7:30 AM EDT - 4 months ago

Zai Lab Announces Participation in Investor Conferences in September 2025

Aug 19, 2025, 7:30 AM EDT - 4 months ago

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Aug 13, 2025, 11:00 AM EDT - 4 months ago

Zai Lab Establishes Oncology Scientific Advisory Board

Aug 7, 2025, 10:29 PM EDT - 4 months ago

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:00 AM EDT - 5 months ago

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 10, 2025, 7:30 AM EDT - 5 months ago

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

Jun 30, 2025, 9:05 AM EDT - 6 months ago

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Jun 13, 2025, 7:00 AM EDT - 6 months ago

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Jun 2, 2025, 7:00 AM EDT - 7 months ago

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 7 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NVCR

May 30, 2025, 7:30 AM EDT - 7 months ago

Zai Lab Announces Participation in Investor Conferences in June 2025

May 28, 2025, 2:48 AM EDT - 7 months ago

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 22, 2025, 11:25 AM EDT - 7 months ago

Zai Lab Limited: Banking On Chinese Pharma Growth

May 19, 2025, 7:00 AM EDT - 7 months ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

May 11, 2025, 8:55 AM EDT - 8 months ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:00 AM EDT - 8 months ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Apr 25, 2025, 1:12 PM EDT - 8 months ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Apr 23, 2025, 10:56 AM EDT - 8 months ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Apr 21, 2025, 7:30 AM EDT - 8 months ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Mar 26, 2025, 7:00 AM EDT - 9 months ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Mar 21, 2025, 5:16 PM EDT - 9 months ago

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Mar 20, 2025, 1:05 PM EDT - 9 months ago

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 12, 2025, 7:30 PM EDT - 10 months ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Mar 3, 2025, 7:30 AM EST - 10 months ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Feb 27, 2025, 10:46 PM EST - 10 months ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 10 months ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Jan 28, 2025, 7:30 AM EST - 11 months ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Jan 22, 2025, 11:15 PM EST - 1 year ago

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Jan 17, 2025, 7:30 AM EST - 1 year ago

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Jan 15, 2025, 7:30 AM EST - 1 year ago

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Jan 10, 2025, 7:30 AM EST - 1 year ago

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

VRTX

Jan 10, 2025, 7:30 AM EST - 1 year ago

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

VRTX

Jan 9, 2025, 6:30 PM EST - 1 year ago

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Dec 26, 2024, 2:31 PM EST - 1 year ago

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 12, 2024, 7:30 AM EST - 1 year ago

Zai Lab Announces Participation in Investor Conference in January 2025

Spartrap Dec. 24 at 5:16 PM

$ZLAB perfect bounce off the lows. Bonus points for the utter stupidity of the ADR crowd👌🏻🔥

0 · Reply

Akwaba76 Dec. 23 at 4:54 PM

$ZLAB 🔥 The market is short-term, science is long-term. COBENFY’s non-dopamine MOA is the biggest innovation in schizophrenia in decades. SP volatility is noise — this is a franchise drug

0 · Reply

Spartrap Dec. 23 at 4:14 PM

1 · Reply

DonCorleone77 Dec. 23 at 2:16 PM

0 · Reply

DonCorleone77 Dec. 23 at 2:13 PM

0 · Reply

Spartrap Dec. 23 at 2:09 PM

1 · Reply

Spartrap Dec. 23 at 2:04 PM

$ZLAB excellent. Just in time to deepen the reversal

0 · Reply

Akwaba76 Dec. 23 at 1:34 PM

$ZLAB Merry X-mas https://www.businesswire.com/news/home/20251223179134/en/Zai-Lab-Announces-Approval-of-COBENFY-xanomeline-and-trospium-chloride-in-China-a-First-in-Class-Therapy-for-Schizophrenia

0 · Reply

Daniels_ Dec. 20 at 4:20 PM

$ZLAB China biotech tracking local sentiment, you need cross border volume and a breakout through resistance before leaning long

0 · Reply

Spartrap Dec. 16 at 6:41 PM

$ZLAB watching this like a hawk. Terrible chart but it makes no sense. Just the Vyvgart licence is worth 10-15% of ARGX MC. Capitulation should be close

1 · Reply

pierke Dec. 16 at 4:01 PM

$ZLAB dirtcheap bought some more

0 · Reply

Tdorsey1776 Dec. 16 at 3:39 PM

$ZLAB B 2k @ $16.85 way way oversold...

0 · Reply

BillionerOfKing Dec. 12 at 4:38 PM

$ZLAB Current Stock Price: $17.96 Contracts to trade: $20 ZLAB Dec 19 2025 Call Entry: $0.18 Exit: $0.24 ROI: 35% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Spartrap Dec. 11 at 9:16 PM

$ZLAB looks like it's headed back to August 24 levels. I made a nice 100% swing at that time.. When one think of all the progresses the co has made since then, the Vyvgart launch, the nice proprietary ADC pipeline, the raise at a high level, it feels a bit silly. I guess that's what politics do to companies when they get caught between the hammer and the anvil 🤔

1 · Reply

TheOrangeBall Dec. 10 at 8:15 PM

$ZLAB Looks like a good entry for a swing here, but my god there's been so much insider selling over the last year wow

1 · Reply

Renzie1 Dec. 10 at 5:13 PM

$ZLAB i keep asking myself, where's the bottom for goodness? Never tought we could sink that hard. Did i miss some info regarding a bad future?

1 · Reply

AlertsAndNews Dec. 7 at 11:04 PM

$ZLAB Zai Lab Announces Updates to China's National Reimbursement Drug List Zai Lab said three of its therapies have been renewed in China’s 2025 National Reimbursement Drug List. VYVGART was renewed for adult patients with generalized myasthenia gravis who are AChR-antibody positive. NUZYRA’s oral formulation was renewed for treating community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. ZEJULA was renewed for maintenance treatment in adult patients with platinum-sensitive, first-line, and recurrent ovarian cancer.

0 · Reply

RunnerSignals Nov. 30 at 8:50 PM

breakouts to watch this week $CRWV $WIX $AXON $ZLAB $VRNS are flirting with breakouts. check them before the moves happen https://stocksrunner.com/news/2025-11-30-technical-breakout-stocks-to-watch-this-week

0 · Reply

Renzie Nov. 20 at 9:32 PM

$ZLAB If this isn't the right time to buy, i don't know if you are ever find a better one! Black friday deals with an extra discount. 50% gains for sure if you only have some patience. Glta

0 · Reply

miguelito87 Nov. 20 at 7:58 PM

$ZLAB $800 million in cash and nearing cash flow positive. So EV is about 1.4billion for this vast pipeline. Only idiots are selling here

0 · Reply

Renzie Nov. 17 at 5:53 PM

$ZLAB What the hell is going on here, keeps dropping every single day. Lost 43% of it's value in 3 months! This is not the zailab as we know it...

0 · Reply

doubleyou2 Nov. 7 at 10:07 AM

$ZLAB So much potential. Impressive pipeline. One day this one will be Big Pharma. But so far it doesn't work out into the right direction. Still holding. Need more patience.

0 · Reply

Market Cap	1.96B
Revenue (ttm)	398.99M
Net Income (ttm)	-257.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-64.44%
Debt to Equity Ratio	0.27

Volume	594,300
Avg Vol	929,078
Day's Range	N/A - N/A
Shares Out	111.96M
Stochastic %K	80%
Beta	0.87
Analysts	Strong Sell
Price Target	$47.36